Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authors' reply to the letter to the editor by Fedai et al.: "Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort".

Pituitary·2026
Same author

Partial or full preservation of the pituitary stalk in craniopharyngioma surgery: improving endocrinological outcomes without an increased risk of recurrence.

Journal of neurosurgery·2026
Same author

Redefining the role of surgery in hypophysitis: Our experience, and a literature review.

Annales d'endocrinologie·2026
Same author

Pituitary Developmental Gene Defects and Their Contribution to Growth Hormone Deficiency.

Annales d'endocrinologie·2026
Same author

Genotype-phenotype correlation and challenges in mutation detection in McCune-Albright syndrome: A retrospective study of a French cohort.

Annales d'endocrinologie·2026
Same author

Unraveling the Genetic Heterogeneity of Isolated Growth Hormone Deficiency: Insights from the GENHYPOPIT Cohort.

Hormone research in paediatrics·2026
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

ACROSTUDY: Status Update on 469 Patients.

Thierry Brue1

  • 1Department of Endocrinology, Université de la Méditerranée and Centre de Référence des Maladies Rares d'Origine Hypophysaire, Hôpital de la Timone, Assistance Publique Hôpitaux de Marseille, Marseille, France. thierry.brue@mail.ap-hm.fr

Hormone Research
|January 21, 2009
PubMed
Summary
This summary is machine-generated.

The ACROSTUDY registry shows pegvisomant effectively normalizes insulin-like growth factor I (IGF-I) levels in acromegaly patients. Long-term safety monitoring in this large cohort indicates manageable adverse events and tumor stability.

Related Experiment Videos

Last Updated: Jun 26, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Area of Science:

  • Endocrinology
  • Pharmacovigilance

Background:

  • ACROSTUDY is an international registry for acromegaly patients treated with pegvisomant.
  • The study monitors long-term safety and efficacy in real-world clinical settings.
  • Patient recruitment grew significantly, with over 469 patients from 10 countries by May 2008.

Purpose of the Study:

  • To assess the long-term safety and efficacy of pegvisomant in acromegaly management.
  • To gather data on pegvisomant treatment patterns and patient characteristics.

Main Methods:

  • Noninterventional, web-based registry.
  • Data collected from over 300 centers across 10 countries.
  • Analysis of patient demographics, prior treatments, pegvisomant dosing, IGF-I levels, and adverse events.

Main Results:

  • High rates of prior treatments including surgery, radiation, and somatostatin analogues.
  • 67% of patients initiated pegvisomant monotherapy.
  • Normal IGF-I levels achieved in 62-78% of patients after 1-4 years.
  • Adverse events reported in 13% of patients; 5.1% experienced tumor size increase.
  • Elevated liver function tests observed in 7.7% of patients.

Conclusions:

  • ACROSTUDY provides valuable insights into pegvisomant use in clinical practice.
  • Further analysis of the ACROSTUDY database will enhance understanding of pegvisomant treatment outcomes.